Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-cash Items (2019 - 2026)

Cytosorbents filings provide 7 years of Non-cash Items readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 50.0% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 50.0% decrease, with the full-year FY2025 number at $1.5 million, down 50.0% from a year prior.
  • Non-cash Items hit $1.5 million in Q4 2025 for Cytosorbents, up from $4.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $8.0 million in Q3 2023 to a low of $4.0 in Q3 2025.
  • Median Non-cash Items over the past 5 years was $4.0 million (2021), compared with a mean of $3.9 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 75.22% in 2021 and later tumbled 100.0% in 2025.
  • Cytosorbents' Non-cash Items stood at $3.9 million in 2021, then changed by 0.0% to $3.9 million in 2022, then increased by 25.37% to $4.9 million in 2023, then tumbled by 38.37% to $3.0 million in 2024, then crashed by 50.0% to $1.5 million in 2025.
  • The last three reported values for Non-cash Items were $1.5 million (Q4 2025), $4.0 (Q3 2025), and $1064.0 (Q2 2025) per Business Quant data.